Non-sense. Management needs to conserve cash in order to milk the company for as long as they can.
FDA didn't even place a hold or issue warning on AFFY's Omontys as it did with ARIA. AFFY voluntarily recalled the drug on its own. Look where it's trading today.
Wishful thinking. The challenges facing ARIA are arguably much more sever than those with AFFY. Additional trials are so prohibitively expensive and time-consuming, ARIA will be forced to abandon Iclusig in the end. Being a one trick pony, it's only fair to evaluate ARIA based on its cash value, which stands at 1.6 and bleeding by the day.
Think again. The instances of one-trick ponies getting slaughtered galore: AFFY, DNDN, etc.
After a few weeks of volatility, ARIA will settle in the 3's if it's lucky.